[New strategies for the treatment of schizophrenia: agonists for DA or glycinergic autoreceptors?].
Vamvakidès
A
A
D018491:Dopamine Agonists / Q000627:therapeutic use*; D018684:Glycine Agents / Q000627:therapeutic use*; D006801:Humans; D018009:Receptors, Glycine / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy*
D018491:Dopamine Agonists; D018684:Glycine Agents; D018009:Receptors, Glycine